#United States #San Francisco #Immunotherapy #Nektar Therapeutics #NKTR-358

Nektar Therapeutics Closes $115 Million Public Offering

On July 2, 2025, Nektar Therapeutics (Nasdaq: NKTR), a biotechnology firm deeply embedded in the clinical research of immunotherapy solutions, announced the successful closing of its underwritten public offering, which raised a substantial $115 million. This capital infusion plays a vital role in advancing their innovative research in immunotherapy and related fields.

Details of the Offering

In total, 4,893,618 shares of common stock were sold at a public offering price of $23.50 per share. The offering also included 638,298 shares sold following the full exercise of an option by underwriters to purchase additional stock. Notably, these shares are integral to supporting the advancement of Nektar's promising drug candidates, specifically in the realms of clinical development and manufacturing costs associated with their extensive research programs.

Jefferies and Piper Sandler acted as joint bookrunning managers for the offering, while BTIG, LLC served as the bookrunner, and H.C. Wainwright & Co. played a prominent role as lead manager.

Anticipated Use of Proceeds

Nektar plans to channel the proceeds from this offering toward general corporate purposes. This encompasses not only the funding of ongoing clinical trials and research but also potentially includes expenses for expanding their immunotherapy pipeline. The company’s focus remains firmly set on addressing the critical needs posed by autoimmune diseases and chronic inflammatory conditions through effective and innovative treatments.

Among Nektar's most notable products is rezpegaldesleukin (REZPEG or NKTR-358), a first-in-class regulator T cell stimulator currently involved in two Phase 2b clinical trials assessing its efficacy for atopic dermatitis and alopecia areata. In addition to REZPEG, Nektar continues its commitment to diversify its pipeline which now includes promising antibody biotherapeutics in different stages of clinical exploration, alongside collaborations directed towards developing agents that could enhance immune responses against cancer.

Legal and Regulatory Framework

The securities issued were made available under a shelf registration statement on Form S-3, previously filed with the U.S. Securities and Exchange Commission on March 28, 2025, and subsequently declared effective. The offering was accompanied by a prospectus supplement, with full details of the offering made accessible through the SEC's website and various brokerage relations.

As a biotechnology enterprise, Nektar emphasizes the significance of forward-looking statements, which are associated with inherent uncertainties and risks. Such statements include anticipated uses of the proceeds which should not be construed as guarantees due to underlying market and operational variables that could impact actual results.

Nektar Therapeutics: A Snapshot

Headquartered in San Francisco, California, Nektar Therapeutics has positioned itself as a key player in the biotechnology sphere. The firm is dedicated to devising treatments that rectify immunological issues pertinent to a spectrum of diseases, thereby contributing to the advancement of healthcare solutions tailored for chronic conditions.

Furthermore, Nektar remains active in its collaborations aimed at evaluating investigational drugs such as NKTR-255, which seeks to enhance the body’s natural defenses against various cancers. Through its innovative research portfolio and successful funding endeavors, Nektar continues to strive toward impactful medical advancements that promise to help improve patient outcomes across diverse indications.

In conclusion, the successful closing of this significant public offering marks a pivotal moment for Nektar Therapeutics, one that could herald advancements in immunotherapy fields while positioning the firm to tackle pressing healthcare challenges with innovative solutions.